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Purpose   
Haematoma expansion is a devastating complication of intracerebral haemorrhage with 
no established treatment. Tranexamic acid had been an effective haemostatic agent in 
reducing post-operative and traumatic bleeding. We review current evidence examining 




We searched MEDLINE, EMBASE, CENTRAL and clinical trial registers for studies 
using search strategies incorporating the terms “intracerebral haemorrhage”, 
“tranexamic acid” and “antifibrinolytic”. Authors of ongoing clinical trials were 
contacted for further details. 
   
Findings 
We screened 268 publications and retrieved 17 articles after screening. Unpublished 
information from three ongoing clinical trials was obtained. We found five completed 
studies. Of these, two randomised controlled trials comparing intravenous tranexamic 
acid to placebo (n=54) reported no significant difference in death or dependency. Three 
observational studies (n=281) suggested less haematoma growth with rapid tranexamic 
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acid infusion. There are six ongoing randomised controlled trials (n=3089) with 
different clinical exclusions, imaging selection criteria (spot sign and haematoma 
volume), time window for recruitment and dosing of tranexamic acid.  
 
Discussion 
Despite their heterogeneity, the ongoing trials will provide key evidence on the effects 
of tranexamic acid on intracerebral haemorrhage. There are uncertainties of whether 
patients with negative spot sign, large haematoma, intraventricular haemorrhage, or 
poor Glasgow Coma Scale should be recruited. The time window for optimal effect of 
haemostatic therapy in intracerebral haemorrhage is yet to be established.   
  
Conclusion 
Tranexamic acid is a promising haemostatic agent for intracerebral haemorrhage. We 
await the results of the trials before definite conclusions can be drawn. 
 
Keywords: tranexamic acid, intracerebral haemorrhage, anti-fibrinolytic, haemostatic 




Spontaneous intracerebral haemorrhage (ICH) is a devastating condition with a median 
30-days mortality rate of 40%.1 It is also associated with significant morbidity with 60% 
of patients remaining dependent one year after the event.1 Haematoma expansion is a 
major cause of early neurological deterioration and poor outcome, occurring in 38% of 
ICH patients within the first few hours from onset of symptoms.2 Nevertheless, patients 
with small haematoma volume have an excellent prognosis.3 Therefore, there is an 
urgent need to direct treatment goal towards limiting haematoma size.   
 
To date, there is no proven treatment to limit haematoma expansion. However, two 
main non-surgical strategies have been postulated to reduce haematoma expansion: 
ameliorating the driving force of haematoma expansion and haemostatic therapy.4 The 
former can be achieved through reduction of perfusion pressure by decreasing systemic 
blood pressure. The INTERACT trial reported reduction in haematoma expansion 
(mean haematoma volume difference of 3.15 mL at 24 hours, p=0.004) in patients 
treated with intensive blood pressure reduction (systolic blood pressure, SBP <140 
mmHg) as compared to standard blood pressure reduction (SBP<180 mmHg).5 In 
addition, The INTERACT 2, ATACH and ATACH-II trials reported non-significant 
reduction in haematoma expansion. However, these did not translate into significant 
reduction in death or dependency.6-8 At the same time, there were concerns that rapid 
blood pressure reduction may result in cerebral ischaemia. The INTERACT, 
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INTERACT 2, ATACH and ATACH-II reported no significant cerebral ischaemic 
events in patients treated with intensive blood pressure reduction.5-8 Current guidelines 
suggest treating blood pressure to a SBP of 140 mmHg is safe and can/may be 
effective.9, 10  
 
Several haemostatic agents have been researched for possible effect in limiting HE. An 
extensively researched haemostatic agent, recombinant activated factor VIIa, was highly 
effective in reducing haematoma expansion but failed to significantly improve clinical 
outcomes in five trials (total patient number =1395), possibly due to a trend towards 
increased thromboembolic complications.11  
 
Tranexamic acid 
Tranexamic acid has been used as an effective haemostatic agent in acute 
gastrointestinal bleeding, menorrhagia, epistaxis, post-cardiac and post-orthopaedic 
surgery.12-16 Besides reducing bleeding rate and need for blood transfusion, tranexamic 
acid also improves healing and reduces inflammation.17, 18   
 
Tranexamic acid has been studied in subarachnoid, subdural and traumatic intracranial 
haemorrhage. In aneurysmal subarachnoid haemorrhage (SAH), tranexamic acid was 
effective in stopping bleeding when use in conjunction with endovascular coiling or 
clipping 19 although an increased risk of cerebral ischaemia offset any benefit.20 Many 
of the trials of tranexamic acid in SAH involved giving high doses of up to 6 g per day 
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for a prolonged duration of three to six weeks and this could have accounted for the 
increased ischaemic events. In view of this, an ongoing trial is examining the efficacy of 
shorter-term tranexamic acid in SAH at lower dose, i.e. 1 g given 8-hourly for a 
maximum of 24 hours.21  
 
The Clinical Randomisation of an Antifibrinolytic in Significant Haemorrhage 
(CRASH-2), a megatrial involving 20,211 patients found that tranexamic acid reduced 
mortality in patients with polytrauma (Odds Ratio, OR 0.91, 95% confidence interval, 
CI 0.85 to 0.97).22 A subgroup analysis of CRASH-2 (n=270) showed that patients with 
traumatic ICH had a non-significant reduction in mortality (adjusted OR 0.47, 95% CI 
0.21 to 1.04).23 An ongoing trial, CRASH-3, is examining the efficacy of tranexamic 
acid in improving outcome after traumatic brain injury.24 An additional trial is testing 
tranexamic acid in the non-surgical treatment of chronic subdural haematoma.25,26  
 
Given these promising results from trials of tranexamic acid in various conditions, we 




The aim was to assess whether tranexamic acid, as compared to placebo or no additional 
treatment, improved outcome in patients with intracerebral haemorrhage? Randomised 
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and quasi-randomised controlled clinical trials, and before-after studies, were included 
and assessed by systematic review and meta-analysis.  
 
Trials were included if they involved adult patients with primary non-traumatic 
intracerebral haemorrhage, i.e. likely to be due to hypertension or cerebral amyloid 
angiopathy. Trials of patients with secondary ICH due to arteriovenous malformation, 
intracranial aneurysm, cavernoma, dural arteriovenous fistula, haemorrhagic brain 
metastasis, trauma or thrombolysis were excluded. Trials could use tranexamic acid at 
any dose, route of administration, and time window for administration. The main 
functional outcomes of interest were modified Rankin Scale (mRS), Barthel Index and 
Glasgow Outcome Scale. Meta-analysis of the primary outcome was performed if at 
least two randomised controlled trials reported relevant data. 
 
Trials were identified in MEDLINE, EMBASE and CENTRAL using search strategies 
incorporating the terms “ tranexamic acid”, “antifibrinolytic” and “intracerebral 
haemorrhage”. No language restrictions were imposed in searches. Searches of 
www.clinicaltrials.gov, the European registry of clinical trials, and WHO international 
clinical trial registry were also performed, these covering both ongoing and unpublished 
trials. Where relevant, experts in the field were contacted for further information 
regarding unpublished data or trials. A complete list of search strategies and results is 
included in the online supplement. 
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Two authors (NS, ZL) independently screened the search results for potential studies. 




Our search identified 268 articles; after deduplication, 163 articles were available for 
screening. Of these, 146 articles were excluded for various reasons (figure 1). The full 
text of 17 articles were extracted and reviewed. A search of clinical trial registers 
revealed nine relevant records of trials, these corresponding to four clinical trials. Some 
clinical trials were registered in more than one trial register. Unpublished information 
on three ongoing studies was obtained from authors. These articles and unpublished 
information described five completed and six ongoing studies that are described in the 
following text.  
 
The five completed studies including two small randomised controlled trials involving 
54 patients. Since these trials did not report sufficiently information on clinical 
outcomes, meta-analysis could not be performed.  
 
Completed observational studies and clinical trials 
Observational studies 
Sorimachi et al reported a retrospective observational before-after study comparing the 
efficacy of rapid infusion of tranexamic acid 2 g over 10 minutes to prolonged infusion 
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of 1 g over 6 hours in patients presenting within 24 hours of ICH. The study recruited 
156 patients (>80% presented within 3 hours of onset) and showed that rapid infusion 
was associated with less haematoma enlargement of >20% than prolonged infusion 
(17.5% vs. 4.3%, p=0.011).27 The authors subsequently reported a study of additional 
95 patients treated with rapid infusion of tranexamic acid with haematoma expansion 
occurring in 4.2% of these patients.28 However, there was no control arm in either 
study.  
 
Ojacastro et al reported an observational study of 30 patients aged 40 to 70 years with 
hypertensive ICH who received either intravenous tranexamic acid 500 mg for 3 doses 
or standard care. The study is reported as an abstract only, with no data other than a 
general statement of significant haematoma volume reduction with tranexamic acid 
without effect on length of stay or in-hospital NIHSS.29 We were unsuccessful in 
contacting the authors for further information. 
 
Randomised controlled trials 
The Tranexamic acid in IntraCerebral Haemorrhage (TICH) trial recruited 24 patients 
within 24 hours (mean 12.6 hours) of ICH to receive either 1 g tranexamic acid or 
placebo over 10 minutes followed by 1 g over 8 hours. There was no 90-day outcome 
difference (mean mRS 3.6 in treatment arm and 3.4 in control, p=0.82) with non-
significantly more haematoma expansion (>6 mL growth) in the treatment arm (19% vs 
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13%).30 However, this trial was designed as a feasibility trial and not to demonstrate 
efficacy.   
 
In addition, Arumugam et al conducted a single centre, single blind randomised 
controlled trial that allocated 30 patients to receive within 8 hours (mean 6 hours) of 
ICH either intravenous tranexamic acid 1 g over 10 minutes followed by 1 g over 8 
hours or placebo. The control group had significant haematoma expansion (median 
growth from 14.53 to 17.59 mL, p=0.001) while the treatment group did not (10.06 to 
10.08 mL, p=0.313).31 The mean Glasgow Outcome Scale score was 3.6 in the control 
and 4.4 in the treatment group, but no statistical tests comparing the groups were 
provided.  
 
Ongoing clinical trials (including those in preparation) 
STOP-AUST. The Spot sign and Tranexamic acid On Preventing ICH growth – 
AUStralasia Trial (STOP-AUST, NCT01702636) is a phase II multicentre randomised, 
double blind, placebo-controlled trial exploring the efficacy of tranexamic acid in 
preventing haematoma expansion in ICH patients, recruiting patients from Australia, 
Finland, and Taiwan.32 The trial selects patients with a positive spot sign on CT 
angiography to receive either placebo or 1 g tranexamic acid over 10 minutes followed 
by 1 g over 8 hours. The primary outcome measure is haematoma expansion (>33% or 
>6 mL) by 24 hours, with mRS and thromboembolic complications at 90 days as 
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secondary outcomes. The trial aims to recruit 100 patients and has recruited 39 patients 
by August 2016.  
 
TICH-2. Tranexamic acid for Intracerebral Haemorrhage-2 (TICH-2, EudraCT number 
2012-004108-37) is a phase III, pragmatic double blind randomised placebo controlled 
trial aiming to recruit 2000 patients in United Kingdom and internationally. The study 
commenced in March 2013 and is due to be completed in December 2017. It has 
recruited 1683 patients as of August 2016. The TICH-2 trial is recruiting ICH patients 
presenting within 8 hours of onset regardless of whether they had CT angiography to 
detect positive spot sign, a predictor of haematoma expansion. Of the patients recruited, 
only 7% (n=103) had CT angiography and of that, 17.5% (n=18) were spot sign 
positive.  The patients are randomised to receive intravenous tranexamic acid 1 g bolus 
(given within 10 minutes) followed by a 1 g infusion given over 8 hours. The primary 
outcome assessed is death or dependency using mRS at 90 days. Secondary outcomes 
include neurological impairment (National Institute of Health Stroke Scale – NIHSS) at 
day 7 or sooner, functional outcome (Barthel index), quality of life (EuroQol, EQ-5D, 
and EQ-VAS), cognition (Telephone Interview Cognition Score-Modified), mood 
(Zung Depression Scale) at days 90 and 365; cost, radiological efficacy and safety 
outcomes up to day 90. Selected centres are invited to participate in an MRI sub-study 
looking at diffusion weighted imaging hyperintense lesions (DWIHL), peri-haematomal 
oedema volume and diffusion restriction at 5 days as well as haematoma cavity volume 
and surrounding gliosis at 90 days.33  
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PATCH-iT is a Danish substudy of TICH-2 aiming to recruit 72 patients with spot sign 
or post-contrast extravasation. Primary endpoint in analysis of this sub-group is 
hematoma volume in spot-sign positive patients, secondary endpoints include difference 
in proportion of neurological deterioration within 24 hours of symptom onset; 
recruitment is starting in July 2016. 
 
NOR-ICH. The Norwegian Intracerebral Haemorrhage Trial (NOR-ICH, EudraCT 
number 2012-005594-30) is a multicentre prospective randomised, open-label, blinded 
endpoint (PROBE) trial. There are two arms in the study: arm A treat patients 
presenting within 2.5 hours from onset and arm B treat patients presenting between 2.5 
to 4.5 hours. The trial recruits spot positive and negative patients. The participants are 
randomised to receive IV tranexamic acid 1 g bolus followed by 1 g at 2 hours, 4 hour 
and 8 hours from the first dose compared to no treatment. The primary endpoint is 
haematoma expansion at 24 hours while secondary endpoints include increase in NIHSS 
score ≥4 within 36 hours, NIHSS at day 7, mRS at 90 days and symptomatic 
thromboembolic events within 7 days. The investigators originally planned to recruit 
540 patients by early 2017. However, the recruitment of patients has been slow, as 
many participating centres have not started recruiting patients yet. 
 
TRAIGE. Tranexamic Acid for Acute ICH Growth prEdicted by Spot Sign (TRAIGE, 
NCT02625948) is a multicentre phase II randomised, double blind, placebo-controlled 
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trial recruiting patients from China who have a positive spot sign on CT angiography 
and can be treated within 8 hours from onset. The trial compares the efficacy of 
intravenous tranexamic acid 1 g followed by intravenous tranexamic acid 1 g infusion 
over 8 hours versus placebo. The primary outcome measure is haematoma expansion 
(>33% or >6 mL) by 24 hours, with mRS and thromboembolic complications at 90 days 
as secondary outcomes. The trial aims to recruit 240 patients by December 2018. 
 
TICH-NOAC. Tranexamic acid for IntraCerebral Haemorrhage secondary to Novel Oral 
AntiCoagulants (TICH-NOAC, NCT02866838) is an investigator-initiated, multicentre 
double-blind placebo controlled trial, investigating the safety and efficacy of tranexamic 
acid in ICH related to non-vitamin K (direct) oral anticoagulants (NOAC).34 The trial 
will include patients from Switzerland who had ICH and taken a NOAC (dabigatran, 
apixaban, rivaroxaban, edoxaban) within the prior 48 hours, or proven NOAC activity 
by relevant coagulation assays. The time window for recruitment is up to 12 hours after 
the onset of ICH. Patients are randomised to received tranexamic acid 1 g bolus 
followed by 1 g infusion over 8 hours or placebo. All patients receive standard 
treatment including specific antidote where available. TICH- NOAC aims to 
demonstrate that treatment with tranexamic acid reduces rate of hematoma expansion as 
measured at 24 hours compared to best medical treatment. The study implementation 
process has started. The first patient is expected to be included in fall 2016 
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EsICH. Tranexamic acid and biomarkers in Emergency management of Spontaneous 
IntraCerebral Hemorrhage (EsICH) is a Romanian multicentre double blind RCT 
recruiting spot positive and negative ICH patients within 8 hours of onset. Patients will 
be given a total of 2 g tranexamic acid or placebo (normal saline, 10mL in total) during 
a course of 8 hours. A series of biomarkers will be tested upon arrival in the emergency 
department (including point-of-care biomarkers for troponin, D-dimer and C-reactive 
protein) to evaluate their role in early risk stratification. The primary endpoint is a 
favourable functional outcome (mRS 0 to 3) at 90 days, assessed by telephone survey. 
The study is awaiting ethical approval. EsICH aims to recruit 100 patients between 
January 2017 and December 2018. 
 
Discussion 
Tranexamic acid is a promising haemostatic agent given its efficacy in reducing 
bleeding rates in surgical and trauma patients. However, there is currently insufficient 
evidence from completed trials to draw conclusion on the effect of tranexamic acid on 
clinical outcome and haematoma expansion (HE) in ICH. The completed trials recruited 
only a small number of patients and did not provide sufficient data for meta-analysis.  
 
Apart from recruiting patients with primary ICH while excluding secondary ICH, the 
six ongoing trials vary in terms of selection criteria, dosing regime and outcome 
assessments. This raises several questions about the design of clinical trials. The first is 
whether tranexamic acid should only be given to patients with positive spot sign? Some 
trials only include patients who had positive spot sign on CT angiography (STOP-
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AUST, PATCH-It, TRAIGE) while others do not (TICH-2, NOR-ICH, TICH-NOAC, 
EsICH). A positive spot sign is an indication of ongoing haemorrhage in ICH, with a 
61% chance of significant HE (>33% or >6 mL).35 However approximately 22% of spot 
sign negative patients also have HE.35, 36 Therefore, excluding spot negative patients 
may unnecessarily preclude them from possible benefits.36 On the other hand targeting 
haemostatic therapy to patients with ongoing haemorrhage only will reduce the number 
of patients unnecessarily exposed to potential thromboembolic complications. As CT 
angiography is not done routinely in ICH in many centres, translation of clinical trial 
results into practice would be easier if spot sign evaluation were not necessary. 
 
The second clinical question is: what is the optimal time window that tranexamic acid 
might be beneficial? Whilst there is no doubt that treatment benefit is time-dependent, 
the exact cut-off time is uncertain.   STOP-AUST and NOR-ICH exclude patients 
presenting later than 4.5 hours, where presumably haematoma expansion would have 
occurred. However, a few considerations should be taken into account here. In a study 
based on serial measurements of hematoma volumes by B-mode ultrasound, haematoma 
expansion was observed up to 7 to 8 hours after symptom onset but most frequently in 
the first hours.37 Brott et al reported that 26% of HE occurred by 4 hours and an 
additional 12% haematoma expansion between 4 and 20 hours.2 By recruiting patients 
presenting later than 4 hours means, a larger pool of patients who may suffer subsequent 
haematoma expansion may be included. In addition, there may be other causes of 
neurological deterioration besides HE such as peri-haematomal oedema and 
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neuroinflammation.38 Tranexamic acid may potentially reduce peri-haematomal oedema 
and attenuate inflammatory response, a process that starts within the first few hours and 
last for days to weeks after ICH. On the other hand, the mega-trial CRASH-2 
demonstrated in trauma patients a strongly time-dependent treatment effect with 
tranexamic acid, with reduced mortality when given within 3 hours and strongly 
increased mortality when given beyond 5 hours, when compared to placebo.39 A clearer 
time window in ICH may be established in the future pending results of ongoing 
studies. 
 
The third question is whether patients with poor prognostic factors should be excluded 
from trials? Such factors include advanced age, poor pre-morbid mRS, poor GCS, 
infratentorial haematoma, high haematoma volume (>60ml or 70ml), intraventricular 
extension and patient undergoing surgery should be excluded from trials? A key point in 
anti-fibrinolytic therapy is it aims to prevent haematoma expansion but not treat 
haematoma expansion after it occurred. It would be logical to exclude patients in whom 
the haematoma expansion have presumably already occurred (high haematoma volume, 
intraventricular extension) or have resulted or would have resulted in poor clinical 
outcome (poor GCS, brainstem haematoma, need for surgery). However, the initial 
haematoma volume in itself is a predictor of haematoma expansion.40 The risk of 
haematoma expansion is greater in large haematoma and as there is no definite way to 
determine whether a rebleeding has stopped, tranexamic acid may still benefit those 
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with poor prognostic factors.40 As customary, we noted that of the ongoing trials, the 
Phase III were more inclusive. 
 
The optimal dosing of tranexamic acid needs to be determined as well. After 
intravenous administration, tranexamic acid reaches peak concentration almost 
immediately and has an onset of action within a few minutes.  It has a short plasma 
elimination half-life of 3 hours. The tissue half-life is 17 hours due to low plasma 
protein binding (3%) and wider distribution in the tissue compartment.41 Repeated 
dosing may result in higher concentration and accumulation in the brain. TICH-2, 
STOP-AUST, TRIAGE, TICH-NOAC and EsICH trials administer intravenous 
tranexamic acid at the same dose similar as the CRASH-2 trial (1g bolus, 1g infusion 
over 8 hours), while NOR-ICH involve giving 1 g tranexamic acid boluses 4 times in 
the first 24 hours. It is not known whether more frequent dosing will result in longer 
accumulation in the target organ or whether this will result in better outcome or more 
adverse events.  
 
The effects of tranexamic acid beyond anti-fibrinolysis remain to be explored. Diffusion 
weighted imaging hyperintense lesions (DWIHL) indicative of acute or subacute 
ischaemic infarcts are known to co-exist in ICH.42 Given the potential of tranexamic 
acid to precipitate ischaemic events, the TICH-2 MRI sub-study explores whether the 
incidence of DWIHL will be higher in those receiving the drug.  Secondly, tranexamic 
acid may have anti-inflammatory and neuroprotective effects. This may reduce peri-
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haematomal oedema and improve healing process manifesting as a reduction in residual 
haematoma cavity and surrounding gliosis.  
 
We plan to resolve the uncertainties concerning the use of tranexamic acid by 
conducting an individual patient data meta-analysis (IPDMA). IPDMA had been shown 
to improve data quality and reliability of effect estimates of several stroke 
interventions.43-45 In addition, a broader meta-analysis of clinical trials encompassing 
the use of tranexamic acid in polytrauma, traumatic brain injury, subarachnoid 
haemorrhage, subdural haemorrhage and spontaneous ICH may provide answers 
regarding the optimal time window and dosage of tranexamic acid. Such a meta-
analysis may provide a more accurate estimation of thromboembolic risk with use of 
tranexamic acid as well.   
 
Conclusion 
In summary, the results of ongoing trials of tranexamic acid for ICH are awaited. Future 
trials should also examine the effect of tranexamic acid on plasma biomarkers and 
pathological changes to determine the effects of tranexamic acid. Prospective meta-
analysis of individual patient data from these on-going trials will provide the most 
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